Table 3 Per-patient sensitivity, specificity, PPV, and NPV for aNC-MRI for LI-RADS 4, 5, and M categories at full protocol including contrast-enhanced sequences
From: HCC screening: assessment of an abbreviated non-contrast MRI protocol
| Â | Pooled | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|---|
Overall | ||||
 PPV | 71/106, 67.0% (57.1–75.6%) | 21/30, 70.0% (50.4–84.6%) | 23/32, 71.9% (53.0–85.6%) | 27/44, 61.4% (45.5–75.3%) |
 NPV | 445/458, 97.2%, (95.1–98.4%) | 151/158, 95.6% (90.7–98.0%) | 151/156, 96.8% (92.3–98.8%) | 143/144, 99.3% (95.6–100.0%) |
 Sensitivity | 71/84, 84.5%, (74.6–91.2%) | 21/28, 75.0% (54.8–88.6%) | 23/28, 82.1% (62.4–93.2%) | 27/28, 96.4% (79.7–99.8%) |
 Specificity | 445/480, 92.7%, (89.9–94.8%) | 151/160, 94.4% (89.2–97.2%) | 151/160, 94.4% (89.3–97.2%) | 143/160, 89.4% (83.3–93.5%) |
Cirrhosis present | ||||
 PPV | 51/61, 83.6% (71.5–91.4%) | 14/15, 93.3% (66.0–99.6%) | 17/20, 85.0% (61.1–96.0%) | 20/26, 76.9% (55.9–90.2%) |
 NPV | 63/71, 88.7% (78.4–94.7%) | 23/29, 79.3% (59.7–91.2%) | 21/23, 91.3% (70.4–98.4%) | 19/19, 100% (79.1–100%) |
 Sensitivity | 51/59, 86.4% (74.4–93.6%) | 14/20, 70.0% (45.7–87.1%) | 17/19, 89.4% (65.5–98.1%) | 20/20, 100% (79.9–100%) |
 Specificity | 63/73, 86.3% (75.8–92.9%) | 23/24, 95.8% (76.9–99.8%) | 21/24, 87.5% (66.5–96.7%) | 19/25, 76% (54.5–89.8%) |
No cirrhosis | ||||
 PPV | 21/47, 44.7% (30.5–59.8%) | 8/16, 50.0% (25.5–74.4%) | 6/12, 50.0% (22.3–77.7%) | 7/19, 36.8% (17.2–61.4%) |
 NPV | 382/386, 99.0% (97.1–99.7%) | 128/129, 99.2% (95.1–100%) | 130/132, 98.5% (94.1–99.7%) | 124/125, 99.2% (95.0–100%) |
 Sensitivity | 21/25, 84.0% (63.1–94.7%) | 8/9, 88.9% (50.7–99.4%) | 6/8, 75.0% (35.6–95.5%) | 7/8, 87.5% (46.7–99.3%) |
 Specificity | 382/408, 93.6% (90.7–95.7%) | 128/136, 94.1% (88.3–97.2%) | 130/136, 95.6% (90.2–98.1%) | 124/136, 91.2% (84.8–95.2%) |
Steatosis present | ||||
 PPV | 8/19, 42.1% (21.1–66.0%) | 3/7, 42.9% (11.8–79.8%) | 2/3, 66.7% (12.5–98.2%) | 3/9, 33.3% (9.0–69.1%) |
 NPV | 88/89, 98.9% (93.0–99.9%) | 29/29, 100% (85.4–100%) | 32/33, 97.0% (82.5–99.9%) | 27/27, 100% (84.5–100%) |
 Sensitivity | 8/9, 88.9% (50.7–99.4%) | 3/3, 100% (32.0–100%) | 2/3, 66.7% (12.5–98.2%) | 3/3, 100% (31.0–100%) |
 Specificity | 22/99, 88.9% (80.6–94.1%) | 29/33, 87.9% (70.9–96.0%) | 32/33, 97.0% (82.5–99.9%) | 27/33, 81.8% (63.9–92.4%) |
No steatosis | ||||
 PPV | 63/87, 72.4% (61.6–81.1%) | 18/23, 78.3% (55.8–91.7%) | 21/29, 72.4% (52.5–86.6%) | 24/35, 68.6% (50.6–82.6%) |
 NPV | 357/369, 96.7% (94.2–98.2%) | 122/129, 94.6% (88.7–97.6%) | 119–123, 96.7% (91.4–99.0%) | 116/117, 99.1% (94.6–100%) |
 Sensitivity | 63/75, 84.0% (73.3–91.1%) | 18/25, 72.0% (50.4–87.1%) | 21/25, 84.0% (63.1–94.7%) | 24/25, 96.0% (77.7–99.8%) |
 Specificity | 357/381, 93.7% (90.6–95.8%) | 122/127, 96.0% (90.6–98.5%) | 119/127, 93.7% (87.6–97.0%) | 116/127, 91.3% (84.7–95.4%) |